New hope to shield down syndrome minds from Alzheimer's?
NCT ID NCT07278492
Summary
This early-stage study is testing the safety of a daily supplement called MIB-626 in adults with Down syndrome. The main goal is to see if the supplement is safe and well-tolerated, while also checking if it raises levels of a key body chemical (NAD+) linked to brain health and aging. Researchers hope this could one day help prevent or slow Alzheimer's disease in this high-risk group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOWN SYNDROME (DS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.